Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

Original reporting
Published Sep 8, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CMNDBullishMed
01

Why it matters

The IRB approval expands the trial to a prestigious site, potentially accelerating data collection and de‑risking the program.

02

Market read

First‑report of a new trial site approval; may influence CMND stock price in the short term.

03

What to watch

Regulatory timelines, competition from other AUD treatments, and financing needs.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Clearmind Medicine is developing CMND-100, a non‑hallucinogenic neuroplastogen for alcohol use disorder.

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

Yale IRB approval enables patient enrollment for Parts B and C of the Phase I/II CMND-100 trial, a new milestone for the company.

Expected impact

Modest upside if enrollment proceeds as expected; risk if delays occur.

Evidence & confidence

IRB approval is a concrete step forward, but trial outcomes remain uncertain.

Market effects

Positive signal for the biotech sector focused on addiction therapies.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche investors.

Counterpoint

Trial enrollment may face operational challenges, and early-stage data could disappoint, limiting upside.

Key entities

  • Clearmind Medicine Inc.

    Biotech firm developing CMND-100 for AUD.

  • Yale University IRB

    Institutional Review Board granting trial site approval.

Related articles

$CMNDMedAI 8/10

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.